, Volume 43, Issue 5, pp 776–798


A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in the Acute Treatment of Migraine and Cluster Headache
  • Kerry L. Dechant
  • Stephen P. Clissold
Drug Evaluation



Sumatriptan is a serotonin1 (5-HT1) receptor agonist, which is effective in the acute treatment of migraine headache. Its antimigraine activity is believed to derive from selective vasoconstriction of cranial blood vessels which are dilated and distended during migraine headache and/or from inhibition of neurogenically mediated inflammation in the dura mater.

In placebo-controlled comparative studies, sumatriptan reduced migraine headache from ‘moderate or severe’ to ‘mild or none’ within 2 hours in 50 to 73% of patients following oral administration of 100 or 200mg, and within 1 hour in 70 to 80% of patients following subcutaneous doses of 6 to 8mg or intranasal doses 20mg into each nostril. In addition, sumatriptan alleviated the accompanying symptoms of nausea, vomiting, and photophobia/phonophobia more effectively than placebo, and permitted higher percentages of patients to resume normal daily activities. Sumatriptan 100mg orally was more effective in the acute treatment of migraine than oral combination therapy consisting of ergotamine 2mg plus caffeine 200mg or aspirin 900mg plus metoclopramide 10mg. Pooled data from nearly 5000 patients treated with either oral or subcutaneous sumatriptan in clinical trials indicate that it is well tolerated.

However, migraine recurrence within 24 or 48 hours of initial symptom resolution developed in approximately 40% of patients treated with sumatriptan, irrespective of route of administration. It is likely that migraine recurrence is related to the short half-life of the drug (approximately 2 hours). Future studies should attempt to ascertain whether additional doses of sumatriptan will help prevent migraine recurrence in patients with attacks of long duration and if so, should determine the optimum interval between dosages.

In conclusion, sumatriptan is an important addition to the range of drugs currently available for acute treatment of migraine. It provides rapid relief from debilitating symptoms in a high percentage of patients, particularly after subcutaneous administration. At this stage in its development a number of questions remain to be answered — most notably whether repeat doses will help prevent recurrent attacks and which patients are most likely to respond to therapy. Nevertheless, sumatriptan presently offers a combination of efficacy and tolerability that is unique in this particular clinical setting.

Pharmacodynamic Properties

The pathophysiology of migraine remains uncertain; however, it is believed that migraine pain arises from excessive dilatation of cerebral blood vessels, particularly those in the dura mater, and/or an accompanying localised sterile inflammatory response mediated by release of vaso-active neuropeptides from sensory fibres innervating these blood vessels. Although evidence to date remains circumstantial, it appears that serotonin is involved in the pathogenesis of migraine. Sumatriptan is a highly selective agonist at a serotoninergic 5-HT1 receptor subtype which mediates constriction of certain cranial blood vessels, and at a prejunctional 5-HT1 receptor subtype which mediates inhibition of neuropeptide release by sensory pain fibres in dura mater. Sumatriptan is virtually devoid of activity at the 5-HT1 receptor mediating cranial vascular smooth muscle relaxation, and at 5-HT2 and 5-HT3 receptors, but has a weak vasoconstrictor effect in the coronary arteries mediated by 5-HT1-like receptors.

Studies in anaesthetised animals have shown that sumatriptan decreases blood flow through carotid arteriovenous anastomoses; however, it is not yet known whether this activity corresponds to the mechanism of action of sumatriptan in humans. In animal species, sumatriptan blocked plasma protein extravasation within the dura mater induced by electrical stimulation of the trigeminal nerve, by inhibiting release of the vasoactive substance, calcitonin gene-related peptide (CGRP). In patients with migraine, elevated CGRP levels were normalised following successful treatment with sumatriptan.

Pharmacokinetic Properties

Maximum plasma concentrations of sumatriptan were achieved at a median of 10 min (range 5 to 20 min) after a single 6mg subcutaneous dose, and at a median of 1.5 hours (range 0.5 to 4.5 hours) after a 100mg oral dose. In healthy volunteers, mean peak plasma concentrations of sumatriptan were 72 μg/L after 6mg subcutaneously, 77 μg/L after 3mg intravenously, and 54 μg/Ltg/L after 100mg orally. The mean bioavailability of sumatriptan was 96% after subcutaneous administration, but only 14% after oral administration, primarily because of extensive presystemic metabolism.

In humans, sumatriptan is 14 to 21% bound to plasma proteins and has a mean apparent volume of distribution of 170L.

Sumatriptan is cleared predominantly by hepatic metabolism, with the major metabolite being the inactive indoleacetic acid analogue. In healthy volunteers, total plasma clearance of sumatriptan following intravenous administration was 72 L/h and renal clearance was 16 L/h. Sumatriptan is excreted predominantly in the urine following subcutaneous administration, but after oral administration, faecal excretion of sumatriptan is increased. Sumatriptan has a mean terminal elimination half-life of approximately 2 hours.

Therapeutic use

Comparative studies have demonstrated that sumatriptan is effective in the acute treatment of migraine with or without aura. A single oral dose of 100 or 200mg produced complete or almost complete relief of headache in 50 to 73% of attacks within 2 hours of treatment. Oral sumatriptan 100mg was significantly more effective in the treatment of migraine than were the oral combination regimens of ergotamine 2mg plus caffeine 200mg, and aspirin 900mg plus metoclopramide 10mg. Subcutaneous sumatriptan 6mg relieved headache in 70 to 77% of patients within 1 hour of treatment, and a 75% response rate at 2 hours was observed in patients treated with intranasal sumatriptan (20mg insufflation into each nostril 15 minutes apart). Compared with placebo, sumatriptan more effectively alleviated the associated symptoms of nausea, vomiting, and photophobia/phonophobia in the majority of patients. However, migraine recurred within 24 to 48 hours of initial resolution in approximately 40% of patients treated with sumatriptan. It is possible that patients with migraine attacks of long duration may benefit from additional doses of sumatriptan, although this awaits confirmation in future studies.

Sumatriptan is also effective in patients with cluster headache. A randomised crossover study reported that subcutaneous sumatriptan 6mg produced significant reduction in headache at 10 and at 15 minutes after administration. At 15 minutes, headache severity was decreased in 74% of attacks treated with sumatriptan compared with 26% of attacks treated with placebo.


Sumatriptan was well tolerated in clinical trials. Adverse events were generally mild and transient and were related to the route of administration. Nausea/vomiting and taste disturbances were the most common adverse events reported by patients after oral administration, although these were partly related to the unpleasant taste of the dispersible tablet used in clinical studies. The dispersible tablet has since been replaced with a film-coated tablet. Brief episodes of mild pain and redness at the site of injection were reported by 40% of patients treated with subcutaneous sumatriptan, and this formulation was associated with higher incidences of tingling, flushing, burning and warm/hot sensations than placebo. Sumatriptan caused feelings of heaviness, and pressure or tightness in the chest and neck, particularly after subcutaneous administration, but the mechanism for these effects is presently unknown. Serious adverse events were rare, although a single case of possible myocardial ischaemia was reported with intravenously administered sumatriptan.

Dosage and Administration

The recommended dosage of subcutaneous sumatriptan in the treatment of migraine is 6mg, administered at the onset of symptoms. If symptoms recur, a repeat 6mg dose may be administered at least 1 hour after the first dose. The maximum recommended dosage of subcutaneous sumatriptan is 12mg during 24 hours. The recommended oral dosage of sumatriptan in the treatment of migraine is 100mg, administered at the onset of symptoms. If symptoms recur, up to 2 additional 100mg doses may be taken during a 24-hour period. The maximum recommended oral dosage is 300mg in 24 hours.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Archives of Neurology 16: 544–552, 1967PubMedCrossRefGoogle Scholar
  2. Brown EG, Endersby CA, Smith RN, Talbot JCC. The safety and tolerability of sumatriptan: an overview. European Neurology 31: 339–344, 1991PubMedCrossRefGoogle Scholar
  3. Buzzi MG, Moskowitz MA. Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihy-droergotamine. Cephalalgia 11: 165–168, 1991PubMedCrossRefGoogle Scholar
  4. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. British Journal of Pharmacology 99: 202–206, 1990PubMedCrossRefGoogle Scholar
  5. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. European Journal of Pharmacology 165: 251–258, 1989PubMedCrossRefGoogle Scholar
  6. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, et al. Treatment of acute migraine with subcutaneous sumatriptan. Journal of the American Medical Association 265: 2831–2835, 1991PubMedCrossRefGoogle Scholar
  7. Chester AH, Martin GR, Bodelsson M, Arneko-Noboin B, Tadjk-arimi S, et al Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries. Cardiovascular Research 24: 932–937, 1990PubMedCrossRefGoogle Scholar
  8. Connor HE, Feniuk W, Humphrey PPA. Characterization of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR43175, a selective 5-HT1-like receptor agonist. British Journal of Pharmacology 96: 379–387, 1989PubMedCrossRefGoogle Scholar
  9. Connor HE, Feniuk W, Humphrey PPA. 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2receptor activation. European Journal of Pharmacology 161: 91–94, 1986CrossRefGoogle Scholar
  10. Connor HE, Humphrey PPA, Feniuk W. Serotonin receptors. Therapeutic prospects in cardiovascular disease. Trends in Cardiovascular Medicine 1: 205–210, 1991PubMedCrossRefGoogle Scholar
  11. Curran DA, Hinterberger H, Lance JW. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxyman-delic acid excretion in normal and migrainous subjects. Brain 88: 996–1009, 1965CrossRefGoogle Scholar
  12. Cutler NR, Hussey EK, Sramek JJ, Clements BD, Paulsgrove LA, et al. Oral sumatriptan in pharmacokinetics in the migrainous state. Cephalalagia 11: 222–223, 1991Google Scholar
  13. Dallas FAA, Dixon CM, McCulloch RJ, Saynor DA. The kinetics of 14C-GR43175 in rat and dog. Cephalalgia 9 (Suppl. 9): 53–56, 1989PubMedGoogle Scholar
  14. Deliganis AV, Peroutka SJ. 5-Hydroxytryptamine1dreceptor agonism predicts antimigraine efficacy. Headache 31: 228–231, 1991PubMedCrossRefGoogle Scholar
  15. den Boer MO, Somers J, Heiligers J, Saxena PR. Arteriovenous anastomotic shunting in the porcine dura mater is not affected by the antimigraine drugs sumatriptan, ergotamine and dihydroergotamine. In Olesen & Saxena (Eds) Serotonergic mechanisms in primary disease, in press, Raven Press, New York, 1992Google Scholar
  16. den Boer MO, Villalón CM, Heiligers JPC, Humphrey PPA, Saxena PR. Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. British Journal of Pharmacology 102: 323–330, 1991CrossRefGoogle Scholar
  17. Doenicke A, Brand J, Perrin VL. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet 1: 1309–1311, 1988PubMedCrossRefGoogle Scholar
  18. Douglas WW. Histamine and 5-hydroxytryptamine (serotonin) and their antagonists. In Gilman et al. (Eds) Goodman’s and Gilman’s The pharmacological basis of therapeutics, 6th ed., p 635, MacMillan Publishing Co., Inc., New York, 1980Google Scholar
  19. Drummond PD, Lance JW. Extracranial vascular changes and the source of pain in migraine headache. Annals of Neurology 13: 32–37, 1983PubMedCrossRefGoogle Scholar
  20. Ensink F-BM. Subcutaneous sumatriptan in the acute treatment of migraine. Journal of Neurology 238: S66–S69, 1991PubMedCrossRefGoogle Scholar
  21. Feniuk W, Humphrey PPA, Perren MJ. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. British Journal of Pharmacology 96: 83–90, 1989PubMedCrossRefGoogle Scholar
  22. Feniuk W, Humphrey PPA, Perren MJ, Connor HE, Whalley ET. Rationale for the use of 5-HT1-like agonists in the treatment of migraine. Journal of Neurology 238: S57–S61, 1991PubMedCrossRefGoogle Scholar
  23. Findley LJ, Abbas A, Bayliss EM. The acute treatment of migraine with aura with sumatriptan. Cephalalgia 11: 226–227, 1991Google Scholar
  24. Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. European Neurology 31: 332–338, 1991CrossRefGoogle Scholar
  25. Fowler PA, Lacey LF, Keene ON, Thomas M. Effect of prophylactic migraine medications on the pharmacokinetic and pharmacodynamic profiles of sumatriptan. Cephalalgia 11: 228–229, 1991CrossRefGoogle Scholar
  26. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. European Neurology 31: 291–294, 1991PubMedCrossRefGoogle Scholar
  27. Fowler PA, Thomas M, Lacey LF, Andrew P, Dallas FAA. Early studies with the novel 5-HT1-like agonist GR43175 in healthy volunteers. Cephalalgia 9 (Suppl. 9): 57–62, 1989PubMedGoogle Scholar
  28. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 338: 13–17, 1991PubMedCrossRefGoogle Scholar
  29. Goadsby PJ, Edvinsson L. Sumatriptan reverses the changes in calcitonin gene-related peptide seen in the headache phase of migraine. Cephalalgia 11 (Suppl. 11): 3–4, 1991Google Scholar
  30. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Annals of Neurology 23: 193–196, 1988PubMedCrossRefGoogle Scholar
  31. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology 28: 183–187, 1990PubMedCrossRefGoogle Scholar
  32. Goadsby PJ, Gundlach AL. Localization of [3H]-dihydroergotamine binding sites in the cat central nervous system: relevance to migraine. Annals of Neurology 29: 91–94, 1991PubMedCrossRefGoogle Scholar
  33. Goadsby PJ, Lambert GA, Lance JW. Differential effects on the internal and external carotid circulation of the monkey evoked by locus coeruleus stimulation. Brain Research 249: 247–254, 1982PubMedCrossRefGoogle Scholar
  34. Goadsby PJ, Piper RD, Lambert GA, Lance JW. Effect of stimulation of nucleus raphe dorsalis on carotid blood flow. I. The monkey. American Journal of Physiology 248: R257–R262, 1985PubMedGoogle Scholar
  35. Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 114: 1001–1011, 1991PubMedCrossRefGoogle Scholar
  36. Goadsby PJ, Zagami AS, Donnan GA, Symington G, Anthony M, et al. Oral sumatriptan in acute migraine. Lancet 338: 782–783, 1991PubMedCrossRefGoogle Scholar
  37. Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Archives of Neurology and Psychiatry 39: 737–763, 1938Google Scholar
  38. Hamel E, Bouchard D. Contractile 5-HT1receptors in human isolated pial arterioles: correlation with 5-HT1dbinding sites. British Journal of Pharmacology 102: 227–233, 1991PubMedCrossRefGoogle Scholar
  39. Hardebo JE. On pain mechanisms in cluster headache. Headache 31: 91–106, 1991PubMedCrossRefGoogle Scholar
  40. Humphrey PPA, Feniuk W, Marriott AS, Tanner RJN, Jackson MR, et al. Preclinical studies on the anti-migraine drug, sumatriptan. European Neurology 31: 281–290, 1991CrossRefGoogle Scholar
  41. Humphrey PPA, Feniuk W, Motevalian M, Parsons AA, Whalley ET. The vasoconstrictor action of sumatriptan on human isolated dura mater. In Fozard & Saxena (Eds) Serotonin: molecular biology, receptors and functional effects, pp.–429, Birk-häuser Verlag, Basel, 1991Google Scholar
  42. Humphrey PPA, Feniuk W, Perren MJ, Connor HE, Oxford AW, et al. GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. British Journal of Pharmacology 94: 1123–1132, 1988PubMedCrossRefGoogle Scholar
  43. Kerber CW, Newton TH. The macro- and microvasculature of the dura mater. Neuroradiology 6: 175–179, 1973PubMedCrossRefGoogle Scholar
  44. Kimball RW, Friedman àP, Vallejo E. Effect of serotonin in migraine patients. Neurology 10: 107–111, 1960PubMedCrossRefGoogle Scholar
  45. Krabbe A. Early clinical experience with subcutaneous GR 43 175 in acute cluster headache attacks. Abstract. Proceedings of the Fourth International Headache Congress, Sydney, 14–18 Oct 41989Google Scholar
  46. Leonhardt S, Herrick-Davis K, Titeler M. Detection of a novel serotonin receptor subtype (5-HT1e) in human brain: interaction with a GTP-binding protein. Journal of Neurochemistry 53: 465–471, 1989PubMedCrossRefGoogle Scholar
  47. Liu-Chen LY, Han DH, Moskowitz MA. Pia arachnoid contains substance P originating from trigeminal neurons. Neuroscience 9: 803–808, 1983PubMedCrossRefGoogle Scholar
  48. McCarthy BG, Peroutka SJ. Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR 43175). Headache 29: 420–422, 1989PubMedCrossRefGoogle Scholar
  49. Moskowitz MA. The neurobiology of vascular head pain. Annals of Neurology 16: 157–168, 1984PubMedCrossRefGoogle Scholar
  50. Moskowitz MA, Buzzi MG. Neuroeffector functions of sensory fibres: implications for headache mechanisms and drug actions. Journal of Neurology 238: S18–S22, 1991PubMedCrossRefGoogle Scholar
  51. Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. European Neurology 31: 314–322, 1991CrossRefGoogle Scholar
  52. Nichols III FT, Mawad M, Mohr JP, Stein B, Hilal S, et al. Focal headache during balloon inflation in the internal carotid and middle cerebral arteries. Stroke 21: 555–559, 1990PubMedCrossRefGoogle Scholar
  53. Oral Sumatriptan and Aspirin Plus Metoclopramide Comparative Study Group. European Journal of Pharmacology, in press, 1992Google Scholar
  54. Oral Sumatriptan Dose-Defining Study Group. Sumatriptan — an oral dose-defining study. European Neurology 31: 300–305, 1991CrossRefGoogle Scholar
  55. Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. European Neurology 31: 306–313, 1991CrossRefGoogle Scholar
  56. Parsons AA, Whalley ET, Feniuk W, Connor HE, Humphrey PPA. 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. British Journal of Pharmacology 96: 434–449, 1989PubMedCrossRefGoogle Scholar
  57. Peroutka SJ. Phytogenetic tree analysis of 6-protein-coupled 5-HT receptors: implications for receptor nomenclature. Neuropharmacology, in press, 1992Google Scholar
  58. Peroutka SJ, McCarthy BG. Sumatriptan (GR 43175) interacts selectively with 5-HT1band 5-HT1dbinding sites. European Journal of Pharmacology 163: 133–136, 1989PubMedCrossRefGoogle Scholar
  59. Perren MJ, Feniuk W, Humphrey PPA. The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia 9 (Suppl. 9): 41–46, 1989PubMedGoogle Scholar
  60. Perren MJ, Feniuk W, Humphrey PPA. Vascular 5-HT1-like receptors that mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetized dogs are not of the 5-HT1aor 5-HT1dsubtype. British Journal of Pharmacology 102: 191–197, 1991PubMedCrossRefGoogle Scholar
  61. Perrin VL, Färkkilä, Goasguen J, Doenicke A, Brand J, et al. Overview of initial clinical studies with intravenous and oral GR43175 in acute migraine. Cephalalgia 9 (Suppl. 9): 63–72, 1989PubMedGoogle Scholar
  62. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. European Neurology 31: 295–299, 1991PubMedCrossRefGoogle Scholar
  63. Ray BS, Wolff HG. Experimental studies on headache. Pain-sensitive structures of the head and their significance in headache. Archives of Surgery 41: 813–856, 1940CrossRefGoogle Scholar
  64. Saito K, Markowitz S, Moskowitz MA. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Annals of Neurology 24: 732–737, 1988PubMedCrossRefGoogle Scholar
  65. Sargent JD. Oral sumatriptan in the acute treatment of migraine: the US experience. Abstract. Proceedings of the Fifth International Headache Congress, Washington, 1 Jul 1991Google Scholar
  66. Saxena PR, Ferrari MD. 5-HT1-like receptor agonists and the pathophysiology of migraine. Trends in Pharmacological Sciences 10: 200–204, 1989PubMedCrossRefGoogle Scholar
  67. Saxena PR, Villalón CM. Cardiovascular effects of serotonin agonists and antagonists. Journal of Cardiovascular Pharmacology 15 (Suppl. 7): S17–S24, 1990PubMedGoogle Scholar
  68. Saxena PR, Villalón CM. 5-Hydroxytryptamine: a chameleon in the heart. Trends in Pharmacological Sciences 12: 223–227, 1991PubMedCrossRefGoogle Scholar
  69. Schoeffter P, Hoyer D. How selective is GR43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1Cand 5-HT1Dreceptors. Naunyn-Schmeideberg’s Archives of Pharmacology 340: 135–138, 1989Google Scholar
  70. Scott AK, Walley T, Breckenridge AM, Lacey LF, Fowler PA. Lack of an interaction between propranolol and sumatriptan. British Journal of Pharmacology 32: 581–584, 1991CrossRefGoogle Scholar
  71. Sicuteri F. Prophylactic and therapeutic properties of 1-methylysergic acid butanolamide in migraine: preliminary report. International Archives of Allergy 15: 300–307, 1959CrossRefGoogle Scholar
  72. Sicuteri F, Testi A, Anselmi B. Biochemical investigations in headache: Increase in the hydroxyindoleacetic acid excretion during migraine attacks. International Archives of Allergy and Applied Immunology 19: 55–58, 1961CrossRefGoogle Scholar
  73. Skingle M, Birch PJ, Leighton GE, Humphrey PPA. Lack of antinociceptive activity of sumatriptan in rodents. Cephalalgia 10: 207–212, 1990PubMedCrossRefGoogle Scholar
  74. Sleight AJ, Cervenka A, Peroutka SJ. In vivoeffects of sumatriptan (GR 43175) on extracellular levels of 5-HT in the guinea pig. Neuropharmacology 29: 511–513, 1990PubMedCrossRefGoogle Scholar
  75. Somogyi A, Gugler R. Clinical pharmacokinetics of cimetidine. Clinical Pharmacokinetics 8: 463–495, 1983PubMedCrossRefGoogle Scholar
  76. Speight TM, Avery GS. Pizotifen (BC-105): a review of its pharmacological properties and its therapeutic efficacy in vascular headaches. Drugs 3: 159–203, 1972PubMedCrossRefGoogle Scholar
  77. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. New England Journal of Medicine 325: 316–321, 1991CrossRefGoogle Scholar
  78. Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. European Neurology 31: 323–331, 1991CrossRefGoogle Scholar
  79. Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. New England Journal of Medicine 325: 322–326, 1991CrossRefGoogle Scholar
  80. Sumner MJ, Humphrey PPA. 5-HT1dbinding sites in porcine brain can be sub-divided by GR43175. British Journal of Pharmacology 98: 29–31, 1989PubMedCrossRefGoogle Scholar
  81. Tansey MJB. Sumatriptan — long term data and future developments. Abstract. Proceedings of the Fifth International Headache Congress, Washington, 1 Jul 1991Google Scholar
  82. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibres containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neuroscience Letters 62: 131–136, 1985PubMedCrossRefGoogle Scholar
  83. Waeber C, Dietl MM, Hoyer D, Probst A, Palacios JM. Visualization of a novel serotonin recognition site (5-HT1d) in the human brain by autoradiography. Neuroscience Letters 88: 11–16, 1988PubMedCrossRefGoogle Scholar
  84. Waeber C, Hoyer D, Palacios JM. GR 43175: a preferential 5-HT1dagent in monkey and human brains as shown by autoradiography. Synapse 4: 168–170, 1989PubMedCrossRefGoogle Scholar
  85. Zagami AS, Lambert GA. Stimulation of cranial vessels excites nociceptive neurones in several thalamic nuclei of the cat. Experimental Brain Research 81: 552–566, 1990CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • Kerry L. Dechant
    • 1
  • Stephen P. Clissold
    • 1
  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations